Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
R RESPIRATORY SYSTEM
R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R03A ADRENERGICS, INHALANTS
R03AL Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
R03AL03 Vilanterol and umeclidinium bromide
D10533 Umeclidinium bromide and vilanterol <JP/US>
USP drug classification [BR:br08302]
Respiratory Tract/Pulmonary Agents
Bronchodilator Combinations
Umeclidinium/ Vilanterol
D10533 Umeclidinium bromide and vilanterol
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
22 Respiratory organ agents
225 Bronchodilators
2259 Others
D10533 Umeclidinium bromide and vilanterol
Drug groups [BR:br08330]
Cardiovascular agent
DG01456 Adrenergic receptor agonist
DG01455 beta-Adrenergic receptor agonist
DG01453 beta3-Adrenergic receptor agonist
D10533 Umeclidinium bromide and vilanterol
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
D10533 Umeclidinium bromide and vilanterol
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D10533 Umeclidinium bromide and vilanterol
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10533
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10533
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10533
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10533
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D10533
